7021-11-6

Basic information

• Product Name: 4-(4-HYDROXYPHENYL)BUTANOIC ACID
• Synonyms: 4-(4-HYDROXYPHENYL)BUTANOIC ACID;4-(4-HYDROXYPHENYL)BUTYRIC ACID;P-HYDOROXYPHENYLBUTANOIC ACID;4-(4-HYDROXYPHENYL)B;4-Hydroxy-benzenebutanoic acid
• CAS NO: 7021-11-6
• Molecular Formula: C₁₀H₁₂O₃
• Molecular Weight: 180.2
• Product Categories: Benzene derivatives
• Mol File: 7021-11-6.mol
• Article Data: 23

Chemical Properties

• Boiling Point: 364.3 °C at 760 mmHg
• Flash Point: 188.3 °C
• Appearance: /
• Density: 1.214 g/cm³
• Vapor Pressure: 6.03E-06mmHg at 25°C
• Refractive Index: 1.567
• Storage Temp.: Inert atmosphere,Room Temperature
• Solubility: Chloroform (Slightly), DMSO (slightly)
• PKA: 4.78±0.10(Predicted)
• CAS DataBase Reference: 4-(4-HYDROXYPHENYL)BUTANOIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(4-HYDROXYPHENYL)BUTANOIC ACID(7021-11-6)
• EPA Substance Registry System: 4-(4-HYDROXYPHENYL)BUTANOIC ACID(7021-11-6)

Safety Data

• Hazardous Substances Data: 7021-11-6(Hazardous Substances Data)

Usage

Uses

4-Carboxypropylphenol is a bacterial chlorophyll derivative.

Synthesis

4-(4-Methoxyphenyl)butyric acid (25g, 129mmol) was dissolved in 48% HBr (125ml) and AcOH (125ml). The resulting solution was heated at 150°C overnight. The resulting mixture was concentrated in vacuo and the residue was dissolved in EtOAc (500ml). The solution was washed with water (500ml), dried (MgSO4) and concentrated to give 4-(4-hydroxyphenyl)butanoic acid as a tan solid.

InChI:InChI=1/C10H12O3/c11-9-6-4-8(5-7-9)2-1-3-10(12)13/h4-7,11H,1-3H2,(H,12,13)

Upstream product

• 56872-39-0 3-(4-hydroxybenzoyl)propionic acid 
• 71597-85-8 (p-hydroxyphenyl)boronic acid 
• 100-66-3 methoxybenzene 
• 4521-28-2 4-(4-Methoxyphenyl)butyric acid 
• 3153-44-4 4-(4-methoxy-phenyl)-4-oxo-butyric acid 
• 22320-10-1 methyl 4-(4-hydroxyphenyl)butanoate 

Downstream Products

• 61439-59-6 2-(4-benzyloxyphenyl)ethanol 
• 6686-26-6 4-(4-benzyloxyphenyl)butyric acid 
• 211857-76-0 4-(4-hydroxyphenyl)butyric acid tert-butyldimethylsilyl ester 
• 184592-40-3 4-(4-Methoxymethoxy-phenyl)-butyric acid methoxymethyl ester 
• 58821-97-9 4-(2,2-dimethylchroman-6-yl)butyric acid 
• 88106-00-7 N-<4-(4-hydroxyphenyl)butyryl>-L-3-carbethoxy-1,2,3,4-tetrahydro-2H-isoquinoline 
• 86778-71-4 N-<4-(4-hydroxyphenyl)butyryl>-L-proline benzyl ester 
• 22320-10-1 methyl 4-(4-hydroxyphenyl)butanoate 
• 35456-35-0 4-(4-hydroxy-3,5-dinitro-phenyl)-butyric acid 
• 882655-14-3 4-(cis-4-hydroxy-cyclohexyl)-butyric acid 
• 192770-60-8 N-{2-[2-(3,4-dimethoxy-phenyl)-1H-indol-3-yl]-ethyl}-4-(4-hydroxy-phenyl)-butyramide 

Relevant articles and documents

Demethylation of 4-methoxyphenylbutyric acid using molten pyridinium hydrochloride on multikilogram scale

4-Methoxyphenylbutyric acid (2) is smoothly demethylated in 3 h at 180°C when melted with pyridinium hydrochloride (Pyr·HCl), affording 4-hydroxyphenylbutyric acid (3), a key starting material for the preclinical candidate LY518674 (1). The adaptation of

Total Synthesis of Tedarene A

Tedarene A is a macrocyclic diaryl ether heptanoid isolated from the marine sponge Tedania ignis showing an inhibitory effect against nitric oxide production. The first total synthesis of tedarene A was achieved starting from the commercially available 3-

Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.